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INTRODUCTION

The need to understand the mechanism of gastric secretion in order
to help patients with peptic ulcer disease brought surgeons to the study
of gastrointestinal physiology early in the history of the field.
main agents cause fundic parietal cells to secrete acid:
gastrin, and histamine.

Three

vagal stimulation,

The action of each can be manipulated and blocked,

and the interdependence among them has therapeutic potential.

The

experimental counterpart of the Zol1inger-El1ison syndrome was created
surgically in dogs, producing hypergastrinemia and gastric hypersecretion.
The effect of parietal cell histamine-2 receptor blockade with metiamide
on the subsequent development of ulcers was studied using a controlled,
cross-over design.
A review of the physiology of the major agonists of gastric secretion
follows.
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REVIEW:

I.

MAJOR AGONISTS OF GASTRIC SECRETION

Vagal Stimulation
In 1814 Sir Benjamin Brodie was perhaps first to observe that vagal

nerve stimulation evoked gastric secretion of acid (55).

In 1858, Claude

Bernard observed that section of the vagus in animals resulted in decreased
gastric secretion and impaired gastric contraction (55).

Surgical treatment

of peptic ulcer during the late 1800's remained limited to gastrointestinal
resection and anastomosis.

In January, 18815 Billroth completed the first

successful pylorectomy for cancer with the anastomosis named for him.

In

November, 1881, von Rydygier performed the first gastrectomy for peptic
ulcer.
At the turn of the century the classic experiments of Pavlov
documented anew the gastric secretory response to vagal stimulation by
sham-feeding, and its disappearance after vagotomy.

Vagotomy in humans by

the abdominal route was introduced in the early 1900's, for a variety of
conditions.

The role of vagotomy in the treatment of peptic ulcer was

little appreciated until, in 1943, Dragstedt and Owens published their
findings in this regard (29).

Dragstedt had observed that patients with

duodenal ulcer showed excessive secretion of gastric juice at night and in
response to food, and tested his hypothesis that vagal hypertonia might
be the cause by performing transthoracic vagotomy in two patients with
duodenal ulcer.

Both experienced a dramatic fall in volume and concentration

of gastric acid secretion, with amelioration of symptoms.

Further reports

from Dragstedt (27) and others followed, confirming his results.

Much of

what we now know about gastric physiology came with the surge of interest
created by his work.
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Vagal stimulation comprises the "cephalic phase" of gastric secretion,
and has three effects:
secrete acid;

1) it directly stimulates the parietal cell to

2) it stimulates cells in the gastric antrum to release

gastrin into the blood, which in turn acts on parietal cells to produce
acid; and 3) it exerts an important permissive or facilitating effect on
gastric secretion, probably at the parietal cell level, which increases
fundic sensitivity to stimuli for acid secretion (86).
All these functions are blocked by vagotomy.

Changes in gastric

secretion after surgical or pharmacological vagotomy have been amply
documented.

Surgical vagotomy (truncal, selective, or proximal gastric)

reduces acid response to pentagastrin and histamine by 60% (110).

Vagal

block with atropine inhibits acid secretion in response to insulin
stimulation in dogs; in increasing doses, atropine inhibits gastrin
release in response to insulin, and in response to feeding (21).
with medical

Patients

(hexamethoniurn and atropine) or surgical vagotomy show decreased

acid response to histamine and to pentagastrin stimulation (69,86).
It is well known and important that non-vagal stimuli for gastrin
release will produce acid secretion in the face of vagotomy, and stimuli
inhibiting gastrin release will counteract vagal stimulation:

for example,

acid in the duodenum inhibits gastrin release and acid secretion in response
to insulin-induced vagal stimulation (21).
Although the limitations of vagotomy alone for duodenal ulcer
disease have become apparent, it remains an essential component of ulcer
surgery.

Gastric emptying is impaired with truncal or selective vagotomy.
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so pyloroplasty, gastrojejunostomy or gastric resection is usually done.
Emptying remains more nearly normal with highly selective vagotomy, so
a drainage procedure is not necessary.

II.

Gastrin
A. Discovery of Gastrin
In 1905 Edkins administered extracts of antral mucosa intravenously

to animals, and observed an increase in gastric secretion, securing the
first evidence for an antral hormone mediating gastric secretion (40). In
1948, Grossman and Ivy demonstrated humoral transmission of the distention
stimulus for fundic acid secretion in dogs (49).
In 1951, Dragstedt, Oberhelman, and Smith (28) demonstrated that
when the antrum of dogs is transplanted to the colon as a diverticulum,
gastric hypersecretion ensues, ultimately producing stomal ulcer at the
gastrojejunostomy margin.

The excess gastric secretion was attributed to

constant release of gastrin due to antral distention and to the lack of
acid inhibition.
The hormone, gastrin, was finally isolated from hog antral mucosa,
identified, and synthesized by Gregory and Tracy in 1964 (45).

Measurement

of gastrin levels by radioimmunoassay was achieved by McGuigan and Trudeau
in 1968 (76), with later advances resulting in a more sensitive assay with
fewer cross-reactions (115).
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B. Nature of Gastrin
Gastrin is contained in specific epithelial cells in the mucosa of
the antrum.

These cells are not distinguished by a particular staining

reaction, but have been identified using fluorescein-labelled antibodies
to gastrin (75).

By electron microscopy (EM) the cells are seen to

contain the labelled hormone in round granules in the cytoplasm (47), which
can be recovered intact for study (33).

Cells containing gastrin by

immunofluorescence are found in the antrum, duodenum, jejunum, and ileum,
in descending order of abundance.

However, cells with the antral cell

structure by EM are few in the duodenum and not seen in the lower small
bowel:

intestinal gastrin is probably secreted by another of the

endocrine-like cells in the gut (94).
The antral gastrin-containing or G-cells of rats have been shown
to empty their granules in response to feeding, with a corresponding rise
in serum gastrin; an hour later, more granules appear, while serum gastrin
stays elevated (70).

In dogs, antral gastrin concentration is not

diminished by feeding (110).
Gastrin exists in several forms (46).

The original form isolated

from hog antral mucosa was a peptide of 17 amino acids, now known as
little gastrin or G17 (see Structure, Table 1).

It is, on a molar basis,

the most potent form, 500 times more powerful than histamine in stimulating
acid secretion.

Later, a peptide of 34 amino acids was identified, and

called big gastrin or G34.

It consists of G17 with a side chain.

G17 and

G34 exist in sulfated and unsulfated moieties, with no difference in
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biological activity.

The carboxy-terminal pentapeptide amide of G17 has

all the biologic actions of the whole molecule (110).
Recently a peptide of thirteen amino acids has been isolated,
named minigastrin or G13; its function is not clear.

Two more forms, of

as yet unknown structure, have high molecular weights and are called
big-big gastrin and Rehfeld Component I; their function is not clear;
they are only weakly physiologically active (110).
The concentration of gastrin in the antrum in man is five times
that in the duodenum, though the larger mucosal area of the duodenum may
counterbalance this (110).

Antral gastrin is 95% G17.

the duodenum and jejunum is 50% G34.

The gastrin in

G17 predominates in tissue, G34 in

serum; big-big gastrin is found in fasting plasma only (89).
releases G17 and G34.
offset (10).

Feeding

G17 has a rapid turnover, G34 a slower onset and

All forms are acted on by trypsin to release G17 (88,116).

Pentagastrin is a commercially available synthetic pentapeptide
consisting of the carboxy-terminal tetrapeptide amide of gastrin, with
beta-alanine and an N-terminal blocking group added.

Its potency is

comparable to that of the carboxy-terminal pentapeptide amide of gastrin (110).

C. Release of Gastrin
A great deal was learned about the antral stimuli for release of
gastrin before the hormone itself was identified.

By 1950 Dragstedt and

coworkers (31) had established that total antrectomy decreased acid
secretion by 86%, while partial antrectomy had no effect; depriving the
antrum of contact with food similarly decreased secretion; and transplanting
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the antrum to the colon produced acid hypersecretion.

They concluded

that the gastric phase of secretion was mediated by gastrin released by the
antrum in contact with food.

In 1952, Storer and coworkers (96,97)

observed that the Exalto-Mann-Wi11iamson procedure produced acid hyper¬
secretion as it produced ulcers, and that antrectomy with vagotomy was
more effective than either procedure alone in preventing ulceration.

In

1964, the year gastrin was identified, Dragstedt and Woodward (32) wrote
that the pathogenesis of gastric ulcer lay in antral stasis, secondary
to vagotomy or pyloric stenosis, or in absence of antral acidification,
secondary to surgical modification of normal anatomy; these conditions
then produced excess gastrin release and acid secretion, resulting in
ulcer.

All these findings concerning the antral release of gastrin have

essentially been confirmed by work utilizing gastrin assays unavailable
then.
Gastrin is released under physiological conditions by 1) vagal
stimulation, 2) distention of either the pyloric or oxyntic gland area,
and 3) antral gastrin-containing cell contact with food (8,23).

1.

Vagal Release of Gastrin
The vagal release of gastrin in dogs was documented by

Nilsson et al

(81) among others, who sham-fed dogs with gastric fistulae

and observed increased serum gastrin and acid secretion.

Acetylcholine

applied topically to the antrum also stimulates acid secretion in dogs,
though this may be by nonvagal pathways (92).

8

Blockade of vagal fibers to the antrum has produced variable results.
In Nilsson's study, atropine diminished the gastrin response to sham-feeding,
and abolished the acid response.

Tepperman (100), studying gastric

fistula dogs, found that surgical vagotomy of the fundus and antrum
abolished the gastrin response to insulin, and diminished the acid response.
The vagal cholinergic pathway in many functions differently, and
may have both stimulatory and inhibitory effects on gastrin release (36,64).
Walsh and coworkers (36), studying normal subjects, found that atropine
decreased acid secretion but increased the gastrin response to insulin.
In further studies (112), atropine also increased gastrin response to
feeding.
Studies in humans after vagotomy (61) (truncal, selective, and
proximal gastric) have documented increased basal gastrin in all types,
up to 57%, attributed to loss of the inhibitory influence of acid secreted
into the antrum.

After vagotomy there is also heightened gastrin response

to feeding, attributed to antral stasis of food stimulating constant
gastrin release.

This heightened response is less in patients who have

had pyloroplasty, with more rapid gastric emptying (61).

It is clear then

that blockade of vagal fibers to the antrum does not decrease gastrin
release when gastrin is stimulated by local factors (12).
Vagal innervation may have a role in the intramural, cholinergic
pathway thought to mediate gastrin release in response to distention, and
possibly mediates acid secretion in response to other, non-gastrin
excitatory or inhibitory stimuli (12,82).
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2.

Release of Gastrin by Distention
The release of gastrin by distention of the stomach has been

confirmed by Debas and Grossman (22), who studied dogs with gastric
fistulae and innervated antral and oxyntic gland area pouches.

They

found that graded distention of the oxyntic pouch, with the antrum
alkalinized, led to graded increases in serum gastrin, and in acid
secretion.

With the antrum acidified, no gastrin was secreted, and much

less acid.

They postulated that antral gastrin was released by an

"oxyntopyloric reflex".

Although possibly alkalinization of the antrum

constitutes in itself a stimulus for gastrin secretion, a recent study
in humans, wherein temporary antral alkalinization produced no increase
in serum gastrin, would tend to refute this (56).

3.

Release of Gastrin by Contact with Food
The component of normal diet primarily responsible for gastrin

release is protein, which is most active after partial digestion to
peptones, and still active as amino acids (110).

Protein and other

chemicals may act on the antral G-cell by direct stimulation of the
microvilli on the luminal surface of the cell, or by neuronally mediated
pathways such as those mediating the distention stimulus for gastrin
release.
4.

Other Stimuli for Gastrin Release
There are some other substances which effect a rise in serum

gastrin for which a physiologic niche has not yet been found.

Calcium
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administered I.V. as the gluconate to normal subjects, increased serum
gastrin 34% and doubled acid secretion (87),

In duodenal ulcer patients,

calcium increased gastrin 94% and acid fivefold.

In patients with

Zollinger-Ellison syndrome, calcium increased gastrin 55%, an important
finding in view of the association between Z-E and hyperparathyroidism.
In a corollary study, the hormone calcitonin, given I.V. to normal
subjects, greatly inhibited gastric secretion and the gastrin response
to food (6).

However, the physiologic role of calcium and calcitonin

in gastric secretion is unknown.
A second substance which increases serum gastrin is epinephrine.
Stadil and Rehfeld (95) reported in 1973 that epinephrine, given I.V. to
normal subjects (25-75 ng/kg), produced a prompt and brief rise in serum
gastrin and in acid secretion which was blocked by prior administration
of beta-adrenergic blocking agents.

They observed that insulin hypo¬

glycemia, as used to test the completeness of vagotomy, caused epinephrine
to rise forty times over basal levels, enough to cause gastrin release
and acid secretion.
Brandsborg et al

(13) studied duodenal ulcer patients before and

after vagotomy and confirmed these findings.

In these patients, the

degree of insulin hypoglycemia attained correlated significantly with
increased plasma adrenalin, which correlated significantly with increased
serum gastrin.

In normal subjects, epinephrine infused to levels seen

with hypoglycemia doubled serum gastrin.

The authors noted the association

between pheochromocytoma and elevated gastrins which fall after resection,
and speculated that epinephrine released by stress might exacerbate ulcer
disease.
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D. Inhibition of Gastrin Release
The secretion of gastric juice by the stomach is inhibited by
the presence in the duodenum of acid, fat, or substances of high or
low osmolarity.

The hormones secretin and cholecystokinin-pancreozymin

(CCK-PZ) have less inhibitory effect (93).
The physiologic mechanisms for inhibiting the release of gastrin
are related, but incompletely understood.
In 1954, Woodward and coworkers showed that acid in the stomach
was a potent inhibitor of gastrin release in dogs (114).

Later, Csendes

and coworkers showed that, in Pavlov and antral pouch dogs, antral
acidification with 0.1 N

HC1 supressed gastrin response to insulin (21).

Antral acidification has since been shown to inhibit gastrin release in
response to most stimulants in dogs:
electrical), topical

vagal

(insulin, sham-feeding,

(protein, acetylcholine), and distention (18).

In man results are less uniform.

Fasting gastrin levels in normal

subjects have been reported unchanged (18) and significantly decreased (39)
by temporary antral acidification.

Serum gastrin in normal subjects and

duodenal ulcer patients has been reported unchanged (65) and significantly
increased (18) after an acidified protein meal.

One consideration is that

the pH equated with acidification has varied from 5.5 to 1.0 in these
studies.

Inhibition of gastrin release is thought to occur most reliably

at a pH of 1.5 or lower (110).
Gastrin release is also inhibited by the gastrointestinal hormones
secretin,

glucagon, and, most recently, GIP (gastrointestinal inhibitory

peptide) and VIP (vasoactive intestinal peptide), a group sharing other
properties in common.
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In 1902, Bayliss and Starling showed that acid in the duodenum
caused release of secretin; in 1904, Sokolov showed that acid in the
duodenum inhibited acid secretion.

In 1957, Dragstedt and coworkers (43)

found that intravenous secretin inhibits the gastric secretion stimulated
by food.

In 1973, Thompson and coworkers (103), studying normal subjects

and patients with duodenal ulcer, found that intravenous secretin suppressed
release of gastrin in response to food.

When given to patients with

Zollinger-Ellison syndrome, secretin dramatically increases serum gastrin,
a finding previously reported as a case study by Isenberg and coworkers
in 1972 (60).
Glucagon has a parallel effect on gastrin.

The Thompson group,

studying normal subjects and patients with duodenal ulcer, found that
intravenous glucagon depresses both basal serum gastrin and the gastrin
response to a standard meal.

Again, in patients with Zol1inger-El1ison

syndrome, glucagon increased basal serum gastrin and did not impair
gastrin response to food (7).
Recent studies (108) have indicated that, given I.V. to Heidenhain
pouch dogs, GIP and VIP do not alter basal serum gastrin but suppress the
gastrin response to food.

Calcitonin, as mentioned earlier, also suppresses

release of gastrin.
The import of these observations is not yet established, but the
possibility that any of these agents functions in the physiologic
regulation of gastrin release and gastric secretion remains open.

E. Deactivation of Gastrin
Circulating gastrin has a disappearance half-life of approximately
eight minutes, less for the G17 fraction, more for G34.

It is deactivated
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or extracted from the blood primarily by the kidney, and to a lesser
extent by the small bowel and secreting gastric fundus.

Little is known

about how gastrin is broken down; intact gastrin is not excreted in the
urine to a significant extent (104).

F. Actions of Gastrin
The primary action of gastrin, which led to its isolation, is
stimulation of the parietal cell of the gastric fundus to secrete acid,
and facilitation of the parietal cell response to vagal stimulation.
Gastrin, however, is prodigal in its actions, although in some it may
not be physiologically important.

(Actions of Gastrin, Table 2).

The trophic effect of gastrin on gastric and duodenal mucosa
and on pancreas, and probably on small bowel and colon mucosa as well,
is independent of its secretory effect (63).

The trophic response is

mediated by synthesis of RNA, protein, and DNA; continued administration
of pentagastrin is followed by mitosis and eventually by hyperplasia of
gastrointestinal mucosal cells both in vitro and in vivo (63).

In

extreme degree, the hypergastrinemia of Zollinger-Ellison syndrome
produces fundic hypertrophy evidenced as the large gastric folds seen
on barium study.
The relationship between gastrin and lower esophageal sphincter (LES)
pressure attracted much attention in an effort to clarify the dysfunction
in esophageal reflux.

In 1972, Lipschutz and coworkers (74), studying

opposums because the LES resembles man's, found that gastrin antiserum
markedly reduced resting LES pressure and LES response to gastrin.
studies again revealed conflicting data.

Human

In fasting normal subjects, serum
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gastrin did not correlate with LES pressure (24).

In two studies, fasting

gastrins in patients with reflux, in comparison with controls, were found
to be significantly lower (73), and not significantly different (37).
Infusion of pentagastrin in normal subjects for an hour produced only
modest increases in LES pressure (39).

Lipschutz (73) found that

alkalinization of the stomach in controls increased serum gastrin sig¬
nificantly and increased LES pressure 118%, but in reflux patients did
not raise gastrin significantly and increased LES pressure only 35%.
Farrell and McGuigan (37), studying patients with reflux and controls,
found that acidification of the stomach caused gastrin and LES pressure
to fall, while alkalinization caused both to rise, in both groups.

They

observed also that the reflux patients released significantly less
gastrin in response to food, and reacted to pentagastrin with significantly
less LES pressure increase, than did controls.

It appeared to these

authors that the LES abnormality in reflux comprised both reduced release
of gastrin, and reduced LES responsiveness to gastrin.

Higgs and coworkers (56),

studying normal subjects, confirmed the pattern of LES response to acid and
alkali in the stomach, but found no rise in gastrin with al kal i ni zation,
and concluded that gastrin has no regulatory effect on LES pressure.
G. Hypergastrinemia
Our ability to identify clinical disorders of gastrin release and
gastric secretion is still, unfortunately, ahead of our understanding of
the normal mechanisms governing these processes.
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Walsh and Grossman (110,111) have recently reviewed the hypergastrinemic disorders.

Hypergastrinemia is seen in the absence of

hypersecretion in 1) atrophic gastritis, particularly with circulating
parietal cell antibodies and achlorhydria (pernicious anemia);
2) gastric carcinoma (77), particularly affecting the body of the
stomach; 3) pheochromocytoma; 4) vitiligo (58); and, rarely, other
conditions.
Hypergastrinemia with hypersecretion is recognized clinically as
the Zol1inger-El1ison syndrome, first described in 1955 (117).

In

this syndrome, an autonomous non-beta-cell tumor of the pancreas produces
gastrin, resulting in chronic hypergastrinemia, massive secretion of
gastric juice, and intractable peptic ulceration, sometimes accompanied
by diarrhea and steatorrhea (59,111).

The tumors are often small, often

metastasize, and contain high concentrations of tissue gastrin.

Serum

gastrins are commonly over 200 pg/ml; G34 predominates (88,89).
The differential diagnosis of increased serum gastrin and excess
acid secretion includes antral G-cell hyperplasia, isolated retained
antrum, gastric outlet obstruction, short bowel syndrome (98) and chronic
renal failure.

Antral G-cell hyperplasia stands intermediate between

Zol1inger-El1ison syndrome and peptic ulcer disease, with increased
fasting gastrin, basal acid hypersecretion, and markedly increased
gastrin response to food, seen in duodenal ulcer disease but not in
Zol1inger-El1ison syndrome (41,83,111).

No evidence for gastrinoma is
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found, but profound hyperplasia of antral G-cells is seen by immuno¬
fluorescence.

These patients do not respond to calcium or secretin

challenge with a rise in gastrin, as do patients with Zol1inger-Ellison
syndrome (99).

The criteria for diagnosis of this condition have not

been determined, and so its incidence is not known.

Its relationship

to Zol1inger-El1ison syndrome and to the more usual forms of peptic
ulcer disease remains to be clarified.
Hypergastrinemia in isolated retained antrum is thought to be due
to gastrin release by the antral cuff, no longer inhibited by gastric
acidification.

In gastric outlet obstruction elevated gastrins are

ascribed to distention of the stomach and to food stasis.

In short

bowel syndrome, and in chronic renal failure, gastrin catabolism may be
impaired, resulting in some degree of hypergastrinemia.

H. Gastrin in Peptic Ulcer Disease
In his 1943 paper on vagotomy for duodenal ulcer, Dragstedt
reported his observation that patients with duodenal ulcer secrete
excess gastric juice at night and in response to food, histamine, or
alcohol

(29).

This basal hypersecretion was ascribed to increased vagal

stimulation, and it diminished after vagotomy.

Still the etiology of

ulcer disease has not been fully elucidated, and the role of gastrin
remains uncertain.
Patients with duodenal ulcer have the same quantity of antral
G-cells as controls (83A), the same gastrin concentration in the antral
mucosa (111), but an increased parietal cell mass (111), possibly in
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response to the trophic effect of gastrin.

Basal serum gastrin levels

in patients with duodenal ulcer, when compared to controls, have been
reported to be not significantly different (110), lower (51), and higher (9).
Patients with duodenal ulcer appear to be more sensitive than controls
to stimulation of gastrin release and acid secretion with pentagastrin (111),
histamine, and calcium.

They secrete acid at a significantly faster rate

than do controls (106).

In view of these findings, Yalow and Berson (9)

theorized that in duodenal ulcer there is a failure of feedback inhibition
of gastric secretion in the face of a high acid secretory rate, and that
the "normal" gastrin levels reflect autonomous release of gastrin from
the antrum.

The circulating gastrin in duodenal ulcer patients has

not been fractionated, but if this theory were true, a larger proportion
of it would be expected to be G17, the most active component, rather than
big-big gastrin, the inactive form which usually predominates in the
fasting state.

III.

Histamine
Histamine was originally synthesized as a chemical curiosity in

1907.

In 1911, Dale and Laidlaw identified the action of histamine on

blood pressure, smooth muscle, and lymph flow.

In 1920, Popielski was

probably the first to discover that histamine stimulated gastric secretion.
In 1927, Best, Dale and others determined that histamine was a natural
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constitutent of the body, and its role in mediating the inflammatory
response was soon documented.

(See Structure, Table 1).

In the early 1940's, Code and coworkers (19,109), verified the
gastric secretory action of histamine in a series of experiments in
which chronic histamine stimulation produced gastric and duodenal
ulcers in animals.

The histamine was administered in doses of 15-60 mg.

given I.M. in a beeswax and mineral oil mixture for prolonged release.
This preparation produced increased secretion of gastric juice in
fifteen minutes which continued for up to 24 hours, and as long as
52 hours.

Daily injections produced erosions or ulcers in all animals

in four days' to four weeks' time.

Code seemed fascinated with this

system and employed it successfully to produce ulcers in dogs, cats,
guinea pigs, chickens, ducks, pigs, calves, monkeys, rabbits, and
woodchucks (20,53,107).
The physiologic role of histamine in gastric secretion is still
debated, but current speculation favors the notion that histamine
functions as a local transmitter and not as a gastric hormone (5,72).
It is stored in gastric mucosa.

Stimuli for acid secretion, including

pentagastrin, cholinergic agents, insulin hypoglycemia, food, and
distention, mobilize histamine, provoke histamine release in the gastric
juice, and increase histamine metabolism (72).

Histamine is thought to

be stored near the parietal cells, and to act on them directly upon its
release.

Parietal cells also contain large amounts of histidine
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decarboxylase, the enzyme which converts histidine to histamine, and
may be activated during gastric secretion (72).

Conceivably, histamine

may not directly stimulate acid secretion, but may act to regulate
gastric mucosal metabolism (62).

A. Histamine Blockade
Stimulation of smooth muscle contraction in gut and bronchi by
histamine is blocked by mepyramine and other conventional antihistaminics (3).
The receptors involved in these mepyramine-sensitive responses are defined
as histamine-1 or HI-receptors.

The action of histamine to stimulate

acid secretion, increase the heart rate, and inhibit contractions in rat
uterus is not deterred by conventional antihistamine blockade (3).
In 1972, Black and associates (11) announced the synthesis of
a compound, burimamide, which blocked these latter actions of histamine
selectively.

The receptors involved in these responses were defined as

H-2 receptors, and the new class of drugs was called H2-receptor antagonist.
The new compounds were chemical modifications of the histamine imidazole
ring, with a thiourea side chain added.

The antagonism of histamine by

burimamide was competitive and specific, without significant interaction
with histamine HI-receptors, catecholamine beta-receptors, or acetylcholine
(muscarinic) receptors.
Burimamide inhibits both histamine- and pentagastrin-stimulated
acid secretion by 80% in humans (11).

However, the drug is inactive

orally, causes release of catechols (2), and has the troublesome side
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effect of vomiting in dogs (57).

It was soon superseded by metiamide,

an H2-antagonist which is well absorbed, active when taken orally,
without immediate side effects or catechol-releasing properties, and a
fivefold more potent inhibitor of acid secretion than burimamide (2,52).
(See Structure, Table 1).
In researching the mechanism of action of metiamide, Code and
Dousa (25) found that, in guinea pig acid-secreting fundic mucosa,
metiamide blocked the stimulation of adenylate cyclase by histamine and
its active derivatives, preventing increased formation of cAMP in response
to histamine.

Metiamide in high concentrations has also been found to

block the uptake and metabolism of histamine by mouse cells in vitro (34).
Burimamide prevents the release of histamine from mast cells in response
to histamine stimulation (71).
The studies of metiamide have revealed information about the
distribution and function of H2-receptors in the cardiovascular system.
Metiamide blocks histamine-stimulated increase in heart rate (1,35),
decrease in blood pressure (1), and vasodilatation in peripheral blood
vessels (44) and in gastric mucosa (5).

Konturek and associates (68)

documented the marked reduction in blood flow which accompanies the
inhibitory action of metiamide on acid secretion in response to several
stimuli.

Albinus (2) confirmed this, and suggested that histamine may

regulate gastric mucosal microcirculation during acid secretion, and that
metiamide blocks this function.

Others (17,72) feel the decreased mucosal

blood flow is secondary to the inhibition of gastric secretion.
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1.

Effect on Gastric Secretion-Animal Studies
The effect of metiamide on gastric secretion was first

evaluated in animal studies which provided a wealth of information.
Given in the absence of secretory stimulation to dogs (42) and cats (52),
metiamide exerted no significant influence.

When secretion was stimulated,

metiamide proved a powerful inhibitor.
Grossman and Konturek (48) gave metiamide I.V. to dogs with
gastric fistulae and Heidenhain pouches, and found it inhibited gastric
secretion during stimulation by histamine, pentagastrin, 2-deoxy-glucose,
and liver extract.

Atropine blocked the response to all but histamine,

but in other studies has blocked response to histamine as well

(48).

Konturek and Rehfeld (68) reproduced these findings using histamine,
pentagastrin, urecholine, and peptone meal as stimulants.

Magee (78)

reproduced them using histamine, pentagastrin, 2-deoxy-glucose, pilocarpine
and food.

Gibson and Hirschowitz (42) found that, given I.V. to dogs as

a background, metiamide inhibited acid secretion in response to histamine,
pentagastrin, 2-deoxy-glucose, and urecholine. Werner and Carter (113),
studying gastric fistula dogs, reported that metiamide, given as a bolus,
drip, or orally, decreased acid output in response to insulin infusion.
Konturek and coworkers (66) studying gastric fistula cats,
found that metiamide inhibited the acid response to histamine by 70%, to
pentagastrin by 55%, to cerulein (an analogue of CCK) by 75%, to peptone
meal by 95%, and to urecholine 100%; though the latter was only a weak
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stimulant of gastric secretion, the others approximated the effectiveness
of histamine.

In an effort to explain these results, Konturek proposed

that the parietal cell has separate receptors for histamine, gastrin,
and acetylcholine, and that blockade of one receptor changes the
properties of one or both of the other two receptors.

He also suggested

that the degree of interaction need not be the same in both directions,
i.e., that blocking the histamine receptor might moderately inhibit
the acetylcholine receptor, while blocking the acetylcholine receptor
might only weakly inhibit the histamine receptor.

Although recognizing

that the histamine blocking activity of metiamide might not in the end
prove to be the property which causes it to inhibit non-histamine stimulants
of gastric secretion, Konturek concluded that the evidence suggested a
physiologic role for histamine in gastric secretion, either as a final
common mediator, as Code has maintained, or as an agent that sets the
responsiveness of the parietal cell to other stimulants, in keeping with
the multiple-receptor model.
In contrast with acid secretion, pepsin secretion in response to
cholinergic and secretin stimulation is actually augmented by metiamide (42,78).
Magee (78) found further that pepsin secretion in response to histamine was
blocked by metiamide, and that gastrin or pentagastrin does not stimulate
pepsin secretion.
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Metiamide has a disappearance half-life of l%-2 hours, and most
animal studies have examined its action over a few hours.

However,

Konturek (67) studied the effect on gastric fistula cats of histamine
or pentagastrin given I.V. for 36 hours, alone or with metiamide.

All

animals (24) that received either stimulant alone developed duodenal
ulcers, ten with perforation or hemorrhage.

When metiamide was given

I.V. as well, much smaller ulcers developed in 1 of 12 cats receiving
histamine, and 3 of 12 receiving pentagastrin.
ulcers in half the animals so treated.

Atropine prevented

Metiamide had no effect on

pancreatic bicarbonate secretion stimulated by exogenous secretin or
duodenal acidification.

2.

Effect on Gastric Secretion-Studies in Man
Because the drug is under experimental controls, studies of

metiamide in humans are few; those done corroborate the findings in
animals.
Carter and coworkers (16,17) produced acid secretion with
intravenous insulin in 6 normal subjects and 4 patients with duodenal
ulcer; metiamide 250 mg. was then given I.V. over 75 minutes.

The

drug produced a marked reduction in volume and acid concentration of
gastric juice, with mean peak acid production in the last hour reduced
by 70% in controls and 76% in ulcer patients compared to baseline.
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Isenberg and coworkers (79) studied 17 patients with duodenal ulcer,
and reported that 1) metiamide in doses of 100,200 or 300 mg. orally
significantly inhibited acid secretion; 2) 200 or 300 mg. decreased acid
secretion by more than 80%; and 3) 300 mg. decreased peptone-stimulated
acid secretion by more than 80%.

Acid inhibition correlated better with

peak blood level than with ingested dose.
was observed.

No change in serum gastrin

Barbezat (4), studying 9 subjects with duodenal ulcer,

found that metiamide 200 mg. decreased pentagastrin-stimulated gastric
secretion by 51%.
Milton-Thompson (80) reported that 11 patients with duodenal
ulcer, metiamide 400 mg. orally on retiring produced profound inhibition
of nocturnal acid secretion in 10.
after taking the drug.

Eight became anacidic for 1-6 hours

pH rose significantly, to well outside the

maximum pH range for pepsin, and remained elevated for six hours.

Serum

gastrin was unchanged.
Pounder and Mi 1ton-Thompson (85) assessed the clinical efficacy
of metiamide in a double-blind study, placing 30 symptomatic duodenal
ulcer patients on metiamide (200 mg. tid and 400 mg. hs), or on placebo,
for 5-8 weeks.

Those on metiamide had less daytime pain; night pain and

antacid consumption were significantly decreased.

Twelve of fifteen on

metiamide were pain-free in the last three weeks of the trial.

3.

Additive Effect of Blocking Agents
The interdependency of histamine and acetylcholine, and of

histamine and gastrin, has been documented (72).

The capacity of metiamide
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or atropine alone to inhibit secretion in response to the major stimuli
is described above.

Recently the interaction of blocking agents in

combination has come under study.

In a study of 16 peptic ulcer patients,

Thjodleifsson (101) reported that atropine augmented and prolonged the
action of metiamide in inhibiting basal and pentagastrin-stimulated
acid secretion in duodenal ulcer patients.
Richardson and Walsh (90) reported that in 7 duodenal ulcer
patients, metiamide 300 mg. with an anticholinergic drug, isopropamide,
was more effective in suppressing food-stimulated acid secretion than
was either drug alone.

Metiamide alone inhibited acid secretion after

a steak meal by 80%; metiamide with a maximum tolerated dose of
isopropamide reduced acid secretion to less than 4.8 mEq/hr for 3 hours
after the meal.

There was no significant effect on serum gastrin or in

gastric emptying with either drug or with the combination.

They

concluded that the effects of the two blocking agents were additive.
Thompson and Reed (105) have concurred that the effect of metiamide and
atropine on gastric secretion is additive.

B. Toxicity of Metiamide
The toxicity of metiamide was first manifested in 1974 in animal
studies when three dogs receiving 81 mg/kg/day developed granulocytopenia
and agranulocytosis with fewer than 500 white cells/mm (15).
dyscrasia proved reversible on withdrawal.

The blood

Studies in humans were undertaken

with careful monitoring of hematologic and other parameters.
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In 1975, Forrest and coworkers (38) reported their experience
with two patients taking metiamide who had developed neutropenia,
heralded by sore throat, malaise and fever, one after metiamide
1200 mg/day for 30 days with 1500 white cells, the other after 800 mg/day
for 99 days with 700 white cells.

The drug was stopped; both patients

recovered clinically within ten days, with gradual hematologic recovery
completed in a month.

Metiamide was suspended from further clinical

trials and permitted for use only in patients with intractable ulcer
disease not amenable to any other modes of therapy.
The toxicity of metiamide has been attributed to its thiourea
side chain, which bears structural resemblance to some of the anti¬
neoplastic chemotherapeutic agents of known hematologic and bone
marrow toxicity.

C. Recent Uses of Metiamide
Metiamide has recently found use in the emergent and long-term
therapy of the Zol 1 inger-El 1 ison syndrome.
In early 1975, Halloway and coworkers (50) reported a case in
which a patient with previous partial gastrectomy and gastrojejunostomy
for duodenal ulcer developed a perforated gastrojejunocolic fistula.
After neogastrojejunostomy a high-output enterocutaneous fistula
developed (6 ltr/24 hr), leading to severe, intractable alkalosis, while
diagnosis of Zol1inger-Ellison syndrome was confirmed by gastrin
assay (=1100).

Metiamide, approved for emergent use by FDA, produced

immediate improvement in blood chemistries, with complete stabilization
and decreased fistula output in 36 hours, permitting successful total
gastrectomy to be performed.
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Richardson and Walsh (91) have treated three patients with
Zollinger-El1ison syndrome, in whom gastrectomy was not an option,
with metiamide (200-300 mg.) alone and with anticholinergics for up
to 6 months.

Metiamide alone effectively decreased acid secretion;

metiamide with an anticholinergic produced near-total inhibition of
acid secretion (2.4-0.1 mEq/30 min) lasting up to four hours.

The

patients' clinical status improved, with rare episodes of ulcer pain,
decreased diarrhea and steatorrhea, no bleeding episodes, and weight
gain in all cases.

No hematologic disturbance was observed.

D. New H2-Receptor Antagonist
The newest H2-receptor antagonist is cimetidine (14), which lacks
the thiourea side chain, and hopefully also the hematologic toxicity
of metiamide.

Cimetidine inhibits acid secretion in the basal state

and in response to histamine, pentagastrin, and carbachol in dogs, and
in response to histamine and pentagastrin in humans (14).

In normal

subjects, cimetidine, 200 mg. orally, inhibits food-stimulated acid
secretion by 54-60% compared to placebo (84).

Henn, Isenberg, and

coworkers (54) studied 7 patients with duodenal ulcer treated with
cimetidine 300 mg. orally.
five hours.

Basal secretion was essentially zero for

Meal-stimulated secretion was inhibited 67%; inhibition

correlated with peak blood cimetidine concentration.
gastrin, and no toxic effect was observed.

No effect on serum

Clearly this group of

compounds has promise for the therapy of ulcer disease.
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THE PRESENT STUDY

At the time this study was undertaken no reports of prolonged
administration of H2-receptor antagonists in patients with ZollingerEllison syndrome were available.

The effectiveness of metiamide in

temporary inhibition of acid secretion had been amply documented, and
the toxicity problem had become apparent.

Our interest turned to

cimetidine, which had recently been released for clinical trials;
however, the drug was not available to us for research purposes,
though metiamide could be readily obtained.
It was decided to study the effectiveness of metiamide in
preventing ulcers when endogenous hypergastrinemia and hypersecretion
were produced by transplanting the antrum to the colon in dogs--an
experimental model of Zollinger-El1ison syndrome.

The procedure,

originally devised by Dragstedt (28,30,31), involves gastro¬
jejunostomy to maintain continuity of the GI tract, and anastomosis
of the isolated antrum to the transverse colon.

The antral mucosa,

stimulated by constant exposure to alkaline colonic contents, secretes
gastrin continuously, producing hypergastrinemia and massive hypersecretion.
Large, progressive ulcers form at the margin of the gastrojejunostomy in
3-12 weeks postoperatively in 85% of animals so treated.

The gastrin

circulating in excess is endogenously secreted and in this the pre¬
paration uniquely resembles the Zol1inger-El1ison syndrome.

The capacity

of metiamide to prevent ulceration in this condition, or to halt or
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reverse the progression of ulcers already formed, would clarify the
potential of H2-receptor antagonists for use in the treatment of
ulcer disease, particularly in the Zol1inger-El1ison syndrome.
(Design of Study with Cross-Over, Table 3).

I.

Materials and Methods

A. Procedure
The antral-transplant procedure was performed in fourteen mongrel
dogs.

The dogs were anesthetized with 25 rng/kg of pentobarbital, and

maintained on a Harvard respirator.
upper abdomen was exposed.
sewn in three layers.

Through a midline incision, the

The pylorus was divided, and each end over¬

Demartel clamps were placed across the junction

of the middle and lower thirds of the stomach, and the stomach divided.
A loop of small bowel was brought up to the stomach, and a point was
chosen for the anastomosis approximately nine inches from the ligament
of Treitz.

An antecolic isoperistaltic gastrojejunostomy was performed

in the Polya manner, using an inner layer of continuous chromic catgut
and a seromuscular layer of inverting silk.
The transverse colon was brought up to the distal antral segment
and a segment of transverse colon was isolated between rubber-shod clamps.
The antral pouch was anastomosed to the colon using the same two layer
technique as above.
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The abdominal cavity was irrigated with saline, hemostasis attained
and the abdominal wall closed in layers with chromic catgut and silk.
A collodion dressing was applied.

Dogs were allowed to recover from

anesthesia and were returned to routine laboratory care. (Completed
Procedure, Figure 1).

B. Gastrin Levels
Preoperative serum gastrin levels were drawn on all dogs, and
postoperative gastrins were drawn on dogs at nine and fourteen weeks
postoperatively.
The gastrin levels were prepared as follows:
overnight.

Dogs were fasted

In the morning, two blood samples were drawn 15 minutes

apart, kept at room temperature for 30 minutes, refrigerated at 6 degrees
Fahrenheit for one hour, centrifuged at 39 degrees Fahrenheit for
twenty minutes at 3000 rpm.

The serum was drawn off and frozen at

-20 degrees Fahrenheit.
The gastrin assays were done by Upjohn Laboratories.
C. Metiamide Preparation
Metiamide was supplied by Smith, Kline and French Laboratories.
Starting on the first postoperative day, the dogs in the control
group were given placebo injections, and those in the drug group were
given injections of metiamide daily.
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The preparation of metiamide in a form suitable to our purposes
was an endeavor of some magnitude.

The drug has a biological half-life

of 1^-2 hours (SK&F, Information for Investigators).

In previous studies

in animals and man it was given as a single oral dose, I.V. bolus or I.V.
drip; people had received oral metiamide (TID and hs) for weeks.

Our

problem was to maintain effective blood levels constantly over a period
of weeks to months in dogs.

As the oral and intravenous routes were not

feasible, we considered the possibility of intramuscular injections of
the drug in a depot vehicle, as is used in Depo-Provera and other drugs.
Inquiries revealed that depot vehicles are not standardized, but tailored
to the medications involved.

The Yale-New Haven Hospital Department of

Pharmacy, while glad to help, pointed out that the pharmacokinetics
of metiamide had been incompletely studied prior to withdrawal of the
drug from clinical studies, and essential data on solubility and
partition coefficients were too limited.

A consult with University of

Connecticut Professor of Pharmacy Dr. Charles Nightingale confirmed
thi s.
When efforts to develop a pharmacologically modern depot form
were thus thwarted, attention was turned to the work of Code, who in
1940 gave dogs injections of histamine in a mixture of beeswax and
mineral oil, and found prolonged release producing gastric acid hyper¬
secretion starting in 15 minutes and lasting up to 52 hours.

In view

of the structural similarity of histamine and metiamide, it seemed
conceivable that the same vehicle might work for us.

With help from the

Department of Pharmacy manufacturing personnel and others, Code's
procedure was duplicated (20).
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The beeswax-mineral oil mixture was prepared in batches.

A

ratio of one part beeswax to four parts mineral oil was used.
Quantities were measured of beeswax, mineral oil

(light weight, USP),

and metiamide in powdered form, sufficient to result in injections of
one cubic centimeter containing 500 mg. of metiamide.
injections, metiamide was omitted.
beaker in a water bath at 100°C.
148-152°C.

In the placebo

The beeswax was melted in a glass
The melting point of metiamide is

The mineral oil was added and mixed in, then the metiamide.

When homogeneous and while still molten, the mixture was drawn up
into one-cc. plastic tuberculin syringes.

Upon cooling to room

temperature, the mixture forms a semi-solid mass, injectable through
a 20 gauge needle.
Code found that multiple small injections were less effective
than two larger ones in releasing histamine evenly over long periods.
Starting on the first postoperative day, dogs received single injections,
in the hind thigh musculature, six days a week.

D. Serum Metiamide Levels
Serum metiamide levels were drawn on three dogs at 0,4,8, and 24
hours after the initial metiamide injection, and at 3,5, and 7 days
thereafter.

Metiamide levels were also drawn on two dogs in the drug

series after prolonged administration of metiamide.

For each metiamide

level, one blood sample was drawn, allowed to clot at room temperature,
and the serum was drawn off and frozen.
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Serum metiamide levels were assayed courtesy of Warren Randolph
of Smith, Kline, and French Laboratories, Philadelphia, Pa.

E. Endoscopy
All dogs were followed for clinical signs of ulceration: weight
loss, loss of appetite, blood in stools.

When a question of ulcer

arose, dogs were endoscoped.
An ACMI 100-cm. single-lumen colonscope was loaned by the
Department of Surgery at the West Haven Veteran's Administration
Hospital for the endoscopy.
overnight.

Prior to endoscopy dogs were fasted

Dogs were anesthetized with pentobarbital

25 mg/kg.

The colonoscope was passed into the esophagus, past the gastroesophageal
junction and into the stomach.

The stomach was inflated with air.

The

fundus of the stomach was visualized, and the gastrojejunostomy stoma
identified.

The endoscope was advanced into the stomal orifice, into

the opening of the efferent loop, and several centimeters down the
efferent loop of the gastrojejunostomy, with air and water insufflation
and suction as needed to maintain a good visualization.

Throughout,

the state of the fundic and jejunal mucosa was assessed, with particular
attention paid to the jejunal mucosa directly opposite the stomal
opening and for the first few centimeters down the efferent loop.

Note

was made of the location and extent of inflammation, erosion, ulceration,
and bleeding of the mucosal surfaces.

When endoscopic evaluation was

complete, the stomach was emptied of air and the colonoscope was gradually

34

withdrawn.

The dog was allowed to recover from anesthesia, and was

returned to the protocol with routine laboratory care.

F. Crossover
Control dogs with endoscopically confirmed lesions were taken
off placebo and crossed over to metiamide treatment.

Dogs in the drug

group were also endoscoped and crossed over, being taken off metiamide,
placed on placebo, and carefully followed for development of ulcers.
All dogs were given routine laboratory care and fed a stock laboratory
diet.

Dogs were followed until demise from perforation of ulcer, or

other causes, occurred, whereupon postmortem examination was performed.

II.

Results
A. Postoperative Mortality
The dogs in the study underwent major surgery with little

postoperative support.

Postoperative mortality was defined arbitrarily

as deaths occurring up to seven days postoperatively.

In the practice

series (7 dogs), and in the protocol series (14 dogs), postoperative
mortality was the same, 43%.
all cases.

Postmortem examination was performed in

Postoperative deaths were attributed to 1) considerations of

technique, primary leaks of the gastrojejunal anastomosis, leading to
peritonitis, and 2) exigencies of postoperative care, particularly wound
infection.
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B. Practice Series
In order to develop adequate technical ability, preliminary
experience with the procedure was obtained in a practice series of
seven dogs.

Postoperative mortality was 43% (3 dogs).

Of four dogs

surviving without complications of surgery, all four were found at
endoscopy or at postmortem to have developed single or multiple
marginal ulcers at the site of the gastrojejunal anastomosis.

The

ulcers were found on the jejunal side, opposite the anastomosis at
the outlet of the stomach, and at distances up to approximately ten
centimeters down the efferent loop.

(See Figures 2 and 3).

In this

series, the mean length of time between operation and documentation
of ulcers was 34 days (range, 9 to 74 days).

C. Protocol Series
1.

Control Group
In the control group of eight dogs, postoperative mortality

was 25% (2 dogs).
Twc other dogs died suddenly, without previous clinical
signs of ulcer and therefore without endoscopy and crossover in medication.
One of these died at seventeen days after the operation.

At postmortem,

this dog had a perforated ulcer of the jejunum opposite the gastrojejunostomy.
The other dog died at ten days after operation.

Postmortem examination

in this dog revealed no reliable findings due to artifacts of freezing
and autolysis; cause of death was not determined.

Of note, in the
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practice series, the shortest time between operation and perforation of
ulcer was nine days, so it is possible that this dog had perforation
at ten days postoperatively.
Four dogs developed weight loss, loss of appetite, and weakness.
These dogs were endoscoped.

At endoscopy all four were found to have

angry red, inflamed gastric mucosae, and severely inflamed, eroded,
exudative and friable jejunal mucosae which bled easily.

Three dogs

had single or multiple jejunal ulcers, ranging in size from lxl cm to
3x2 cm.
opening.

The fourth dog had one large erosion opposite the stomal
Mean length of time from operation to documentation of ulcer

was 18 days (range, 14-22 days).
These four dogs were crossed over.

Placebo injections were

stopped, and injections of metiamide, 500 mg. daily, were begun.
Little improvement in clinical status was observed.
eventually succumbed to perforation.

All four dogs

Mean length of time between

starting metiamide and death was 12.5 days (range, 7-17 days).
Mean length of time between operation and demise in these four
dogs was 31.25 days (range, 22-39 days).

Mean weight loss between

operation and endoscopy was 24% of preoperative body weight (range,
20 to 26%).
2.

Drug Group
In the drug group of six dogs, postoperative mortality was

67% (4 dogs).
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Two dogs surviving without complications of surgery were placed
on metiamide 500 mg. INI daily starting directly postoperatively.
dogs survived for an extended period.

These

One dog experienced minimal

weight loss (6% of preoperative body weight); one, significant weight
loss (51%).

Both were endoscoped fourteen weeks after operation, at

102 and 104 days postoperatively.

At endoscopy each dog was found to

have a single, small, superficial erosion of the jejunum, one opposite
the anastomosis, and one a few centimeters down the efferent loop.
The gastric and jejunal mucosaeotherwise appeared normal, blue-pink,
moist and glistening, without inflammation, friability or bleeding.
No ulcers were seen.
These dogs were crossed over.
and placebo injections begun.

Metiamide injections were stopped,

One dog (with 6% weight loss) died of

perforated jejunal ulcer 10 days after stopping metiamide.

The other dog

is still alive and being followed; this dog has significant weight loss.

D. Gastrin Levels
The mean preoperative serum gastrin level for all dogs was 42.5 pg/ml,
(range, 11 to 68 pg/ml).
is less than 120 pg/ml.

Normal range for the laboratory doing the assay
Postoperatively serum gastrin rose to a mean of

454.3 pg/ml, (range, 431 to 500 pg/ml).

E. Metiamide Levels
The assay for serum metiamide level revealed that detectable
circulating levels of metiamide were not present in any of the samples.

However, in dogs, metiamide may circulate in amounts which are effective
in suppressing acid secretion but which are not detectable by the assay
developed for the drug (see Discussion).

III.

Discussion

A. Effectiveness of Procedure
Our study reconfirmed the original findings of Dragstedt that
transplantation of the antrum to the colon produces hypergastrinemia,
hypersecretion and marginal ulceration at the site of the gastrojejunostomy
Gastrin levels had not to our knowledge

been done in connection with

this procedure, and our data reveal that postoperatively serum gastrin
ascends to the Zollinger-Ellison range (400-500 pg/ml), in keeping with
the progressive nature of the ulcers produced.
The ulcerogenic effectiveness of the procedure in our hands was
comparable to the results reported earlier.

Of those dogs surviving the

postoperative hazards posed, all four of four in the practice series,
all four of four in the control series, one (control) which perforated
before crossover, and one of two in the drug series, all off metiamide,
developed ulcers of the jejunal mucosa near the gastrojejunostomy.
B. Metiamide Findings
The report from Smith, Kline and French Laboratories that no
detectable amount of metiamide was found in the serum samples according
to their assay deserves some amplification.

The SK&F Laboratory staff

reports that amounts of metiamide which effectively inhibit gastric
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secretion may circulate at levels too low to assay.

For our purposes,

this leaves two possibilities: 1) no metiamide was released from the
beeswax vehicle, and none was circulating; or 2) the dogs had effective,
but not detectable serum levels of metiamide.

Thus, the amount of

metiamide circulating is not known, though it must be less than the
assay can detect; similarly, its effectiveness in suppressing acid
secretion when given intramuscularly is not established.

In retrospect,

it appears that acid studies would be a useful adjunct in evaluating
therapy with this drug-vehicle combination.

We have based our conclusions

regarding effectiveness of intramuscular metiamide on other data from
the study.

C. Control Group
The control dogs in our study developed ulcers on placebo in an
average of 18 days, with associated weight loss averaging 26% of
preoperative body weight, lived an average of 12.5 days longer on
metiamide, and died an average of 31 days after operation.
These results can be explained by one of three hypotheses.
One: metiamide as administered did not decrease acid secretion, and
the progression of ulcers was unchecked.
and this cannot be verified.

Acid studies were not done,

Two: metiamide did decrease acid secretion,

and the dogs survived longer because of this.

This also cannot be

verified; one could not know how long an interval between ulceration
and perforation to expect.

The ulcers develop at widely varying rates;

in the original study the length of time to perforation was 21-100 days.
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in ours 9-74 days.

In three dogs in this study (2 practice and 1 control)

that went from operation to perforation without intervention, the average
course was 33 days (range, 9-74 days).

Although the pool is small, it

does not seem that metiamide delayed perforation in the control dogs,
however no case of healing of existing ulcer was observed.
The third possibility is that metiamide did decrease acid
secretion, but the ulcers, some massive, were far advanced, and in the
face of severe weight loss, without other therapeutic or nutritional
support, were unable to heal, and so went on to perforate.

D. Drug Group
The two dogs in our drug group developed no ulcers in 102 and 104
days on metiamide, with weight loss of 51% and 6% respectively; after
being taken off metiamide, one dog lived 10 days; the other is still
being followed.
These results might be explained by any of three hypotheses.
The first is that metiamide had no effect, and the animals were just
slow to develop ulcers.

Several observations go against this.

The

length of time to perforation (114 days) is longer than any seen by
Dragstedt, or elsewhere in our series.
is possible, it seems unlikely.

Although such a long interval

The normal findings at endoscopy also

go against this, although possibly an ulcer was missed which later
perforated.

Further, that this pattern should occur only in drug dogs
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and in none of the controls is highly unlikely, although such small
samples are not amenable to tests of statistical significance.
The second hypothesis is that metiamide did inhibit gastric
secretion, but the prolonged survival is due to other factors.

In

Dragstedt's series, 15% of dogs did not have ulcers at postmortem;
the reasons for this were not clear.

Some animals were sacrified,

and not followed for maximal periods of time.

In a study in which the

antrum was transplanted with its vagal innervation preserved, ulcers
did not develop; thus, vagal inhibitory influences may play a role
under certain conditions (64).
The third possibility is that metiamide decreased acid secretion,
and this prolonged survival in the drug group dogs.

The drug dogs

lived more than three times longer than the controls and remained
ulcer-free until taken off the drug.
varying rates.

Off metiamide, ulcer appears at

The earliest documented ulcer in the practice series

was at nine days; one drug dog off metiamide perforated at 10 days.
The latest ulcer was at 74 days in our series, 100 days in Dragstedt's;
the second drug dog, being followed, is within this range.
The question of metiamide release from the vehicle is nagging.
Code found that histamine given in the same manner produced increased
gastric secretion within 15 minutes.

Metiamide given intravenously has

immediate effect; taken orally, the drug acts in 1-1^ hours (90,91).
In our study, the dose of 500 mg. was ample, on a mg. per kg.-hr basis,
to inhibit acid secretion for 24 hours in dogs, if it all reached the
bloodstream.

Therefore, we were dismayed to witness the downhill course
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of the control dogs after cross-over; however, the advanced state of
the ulcers may have been etiologic.

The prolonged survival of the

drug animals while on metiamide supports the contention that enough
metiamide was released to keep acid secretion below the ulcerogenic
level, providing effective prophylaxis against ulceration.

IV.

Conclusions
Our study indicated that when metiamide was given IM in a beeswax

vehicle to dogs with established hypergastrinemia and hypersecretion,
with ulcer, it did not permit healing, and could not be shown to have
effectively delayed progression of the ulcers to perforation.

However,

when the drug was started postoperatively, it appeared to confer
protection against ulceration for up to 14 weeks in the face of significantly
elevated gastrin levels.

After discontinuing metiamide, ulcer developed

at individual rates.
These results are in keeping with most findings on metiamide.
The only previous study of metiamide in hypergastrinemic animals was done
by Konturek (67), who gave metiamide and pentagastrin intravenously for
36 hours to gastric fistula cats.

Pentagastrin given alone produced

ulcers in 12 of 12 animals, five with perforation or hemorrhage.
Pentagastrin given with metiamide produced smaller ulcers in 3 of 12 cats.
Our results appear to corroborate this prophylactic effect of metiamide
on ulcer formation.
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In humans, because of experimental controls on its use, few
studies of the effect of long-term metiamide therapy have been done.
An oral regimen of metiamide has proven effective in reducing ulcer
pain and antacid consumption in duodenal ulcer patients over eight
weeks (85).

Oral metiamide, with an anticholinergic, has also proven

effective in the management of patients with the Zollinger-El1ison
syndrome for up to six months, with marked inhibition of acid
secretion, reduced ulcer pain, diarrhea, and steatorrhea, prevention
of bleeding episodes, and weight gain (91).

Given over extended periods,

metiamide may block not only the acid secretory effect but also the
trophic effect of gastrin on the parietal cell, producing a degree of
parietal cell atrophy and diminished secretion on this basis as
well.

It would appear that patients on a regimen of oral metiamide

experience some degree of ulcer healing, although this has not been
documented.

In our study daily metiamide IM did not permit ulcer healing.

This represents either a problem of drug administration, resulting in
incomplete inhibition of acid secretion, or a result of the advanced
nature of ulcer disease in our control animals, which mandated more
vigorous therapy for cure.
The results of our work and that of others confirms that the
H2-receptor antagonists promise much for therapy of gastric secretory
disorders.

Cimetidine, the H2~receptor antagonist currently under study,

blocks acid secretion as well as metiamide, and may prove to be without
serious side effects and toxicity.

In that case the therapeutic potential

of cimetidine and its future congeners is considerable, and these agents
would expectably influence treatment of hypersecretory conditions of
diverse etiologies.

44

It seems sadly ironic for surgeons, who played an early, crucial,
and ongoing role in advancing our understanding of gastric secretion and
its disorders, to be now presented with most promising improvements in
the medical treatment of ulcer disease.

Yet it may be expected that,

as before, a combination of medical and surgical care will optimally
benefit the ulcer patient.

In the case of metiamide, the recent observation

that anticholinergics augment and prolong metiamide effectiveness is
tempered by the problem of accompanying atropinic side effects.

The

anticholinergic effect desired might obtain from vagotomy, either truncal,
selective, or proximal gastric.

H2-receptor blockade might then provide

maximal adjunctive therapy, being without known immediate side effects,
with clinical advantage to the patient.

The etiology and therapy of ulcer

disease will continue to be studied and debated, hopefully with further
benefit to people who suffer its manifestations.

Figure 1

Antral Transplantation Procedure with Antrum-to-Colon
Anastomosis and Gastrojejunostomy.

Figure 2:

Gross specimen from an animal that succumbed to multiple
stomal ulcers, one of which had perforated, producing
generalized peritonitis.

Figure 3:

Section through one edge of a perforating ulcer in the
efferent 1tmb of a gastrojejunostomy. Note scarring
and acute and chronic inflammation.

TABLE 1
STRUCTURES OF PARIETAL CELL AGONISTS:
GASTRIN, ACETYLCHOLINE, HISTAMINE, and METIAMIDE

GASTRIN (G17)

Pyr- Gly- Pro- Trp- Leu- GluGIu- Glu- Glu- Glu- Ala- TryGly- Trp- Met- Asp- Phe- NH„

;h3
!—CH

ACETYLCHOLINE

3

:H„

HISTAMINE

METIAMIDE

CH3-r.

■CH2—S—CH2-—NH—C—NH—CH3

II

TABLE 2
ACTIONS OF GASTRIN

Water & Electrolyte Secretion
Stomach
Pancreas
Li ver
Small Intestine
Brunner's Glands

Enzyme Secretion
Stomach
Pancreas
Small Intestine

Inhibition of Water, Electrolyte
and Glucose Absorption
Small Intestine

Stimulation of Smooth Muscle
Lower Esophageal Sphincter
Stomach
Small Intestine
Colon
Gall Bladder

Inhibition of Smooth Muscle
Pyloric Sphincter
Ileocecal Sphincter
Sphincter of Oddi

Release of Hormones
Insulin
Caleitenin

Increase in Blood Flow

Stomach
Small Intestine
Pancreas

Trophic Action
Gastric Mucosa
Small Intestine
Pancreas
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abstract

Metiamide, an H2-receptor antagonist, has been found to inhibit
acid secretion in duodenal ulcer patients (4,16,17,79,80,85).

In an

effort to evaluate its possible use in treatment of the Zollinger-Ellison
syndrome, the effect of prolonged administration of metiamide on
formation of ulcers was studied in dogs with hypergastrinemia and hyper¬
secretion secondary to transplantation of the antrum to the colon, an
ulcerogenic preparation devised by Dragstedt (28,30,31).

Metiamide was

given, 500 mg. IM daily, in a beeswax vehicle for prolonged release
devised by Code (19,109).
The antral transplant procedure was performed in 14 dogs.
operative mortality was 43%.

Post¬

Postoperative serum gastrin levels were

elevated into the Zol1inger-Ellison range--400 to 500pg/ml. All four
animals in the control group, on daily placebo injections, developed
ulcers, confirmed endoscopically, an average of 18 days after operation.
They were then "crossed-over" and placed on metiamide, lived an average of
12.5 days longer, and succumbed to peritonitis secondary to perforated
stomal ulcer.

The two animals in the drug group, on daily metiamide

injections, were ulcer-free by endoscopy done 102 and 104 days after
operation.

They were taken off drug and placed on placebo injections.

One dog died of perforated stomal ulcer after 10 days on placebo.
other is still being followed (82 days on placebo).

The

Serum metiamide levels

were equivocal.
It appears that metiamide does not promote healing of existing ulcers,
but protects against ulcer formation in this preparation.

Clinical

usefulness of H2-receptor antagonists in therapy of Zol1inger-Ellison
syndrome is discussed.
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